125 related articles for article (PubMed ID: 11456300)
1. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease.
Andreassen OA; Ferrante RJ; Huang HM; Dedeoglu A; Park L; Ferrante KL; Kwon J; Borchelt DR; Ross CA; Gibson GE; Beal MF
Ann Neurol; 2001 Jul; 50(1):112-7. PubMed ID: 11456300
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
[TBL] [Abstract][Full Text] [Related]
3. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
4. Lipoic acid improves survival in transgenic mouse models of Huntington's disease.
Andreassen OA; Ferrante RJ; Dedeoglu A; Beal MF
Neuroreport; 2001 Oct; 12(15):3371-3. PubMed ID: 11711888
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
[TBL] [Abstract][Full Text] [Related]
6. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease.
Andreassen OA; Dedeoglu A; Ferrante RJ; Jenkins BG; Ferrante KL; Thomas M; Friedlich A; Browne SE; Schilling G; Borchelt DR; Hersch SM; Ross CA; Beal MF
Neurobiol Dis; 2001 Jun; 8(3):479-91. PubMed ID: 11447996
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.
Vamos E; Voros K; Vecsei L; Klivenyi P
Biomed Pharmacother; 2010 Apr; 64(4):282-6. PubMed ID: 19932584
[TBL] [Abstract][Full Text] [Related]
8. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
9. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
[TBL] [Abstract][Full Text] [Related]
11. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
[TBL] [Abstract][Full Text] [Related]
12. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse Model.
Jiang W; Wei W; Gaertig MA; Li S; Li XJ
PLoS One; 2015; 10(7):e0134142. PubMed ID: 26225560
[TBL] [Abstract][Full Text] [Related]
14. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
Hickey MA; Reynolds GP; Morton AJ
J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
[TBL] [Abstract][Full Text] [Related]
15. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
[TBL] [Abstract][Full Text] [Related]
16. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Zádori D; Geisz A; Vámos E; Vécsei L; Klivényi P
Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
[TBL] [Abstract][Full Text] [Related]
17. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.
Cheng Y; Peng Q; Hou Z; Aggarwal M; Zhang J; Mori S; Ross CA; Duan W
Neuroimage; 2011 Jun; 56(3):1027-34. PubMed ID: 21320608
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease.
Decressac M; Wright B; Tyers P; Gaillard A; Barker RA
Exp Neurol; 2010 Nov; 226(1):24-32. PubMed ID: 20673761
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
Naia L; Cunha-Oliveira T; Rodrigues J; Rosenstock TR; Oliveira A; Ribeiro M; Carmo C; Oliveira-Sousa SI; Duarte AI; Hayden MR; Rego AC
J Neurosci; 2017 Mar; 37(10):2776-2794. PubMed ID: 28123081
[TBL] [Abstract][Full Text] [Related]
20. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice.
Dedeoglu A; Kubilus JK; Yang L; Ferrante KL; Hersch SM; Beal MF; Ferrante RJ
J Neurochem; 2003 Jun; 85(6):1359-67. PubMed ID: 12787055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]